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Background: India accounts for 23% of the global incidence of TB cases; it also has an estimated 2.3 million HIV
infections. Of the 2 million TB incident cases, 5% occurred in HIV infected persons. The country has large national
TB and HIV control programs. This paper describes characteristics of TB-HIV co-infection cases registered under the
program in Karnataka province, India. Treatment outcomes for coinfected patients are compared with those for TB
patients in the province.
Methods: Program reports from the National AIDS Control program and the National TB control program for
Karnataka province (a high HIV prevalence state, population 61 million) were analysed. Data from patients registered
in each program in 2010–2011 was studied.
Results: Of the 6,480 adult co-infections, a third occurred in women; 78% of patients were initiated on ART. Among
the cohort 73% had pulmonary TB, and 46% reported sputum positivity for acid fast bacilli. Treatment success
among co-infected patients not on ART (54%) were significantly lower compared to those already on ART (80%);
death and default rates were higher in the non-ART group. Treatment success proportions (75%) for the co-infected
patients were similar to those for the 51,966 patients registered under the TB program. Death rates among
co-infected patients (15%) were twice as high as for TB patients under the program, though default and
failure rates were lower.
Conclusion: Co-infected patients already on ART demonstrated better TB outcomes in than those not on
ART. Compared to those with TB only, co-infected patients had similar TB treatment success rates and lower
rates of treatment default and failure. Integration of TB-HIV collaborative activities will strengthen our battle to
control TB and HIV globally.
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The convergence of the tuberculosis (TB) and the HIV
epidemics pose new public health challenges [1]. The
interaction between HIV and TB in co-infected persons
is bidirectional and synergistic; on one hand, HIV-1 infec-
tion predisposes to the development of active TB, and, on
the other, the course of HIV-related immunodeficiency
is worsened by active TB infection [2]. TB is the most* Correspondence: susha007@gmail.com
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reproduction in any medium, provided the orcommon opportunistic infection seen in HIV patients as
well as a leading cause of death in these patients. The
lifetime risk of TB in immune-competent persons is
5-10% whereas in an HIV-infected person, the annual
risk of TB is 5-15% [3].
India has the highest TB burden in the world and
accounts for 23% of the global incidence of TB cases
i.e. 2 million of the 8.8 million incident cases in 2011
were from India [4]. A recent paper estimated that nearly
5% of the 2 million TB incident cases were HIV seroposi-
tive [5]. While the HIV epidemic in the country is showingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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infections from 1996 levels [6], there are still an estimated
2.27 million people living with HIV infection [7]. India has
well-structured and functional national programs for the
control of both HIV and TB; the National AIDS Control
Program (NACP) and the Revised National TB Control
Program (RNTCP) respectively. The country has established
cross-referral mechanisms in most provinces, where
NACP has implemented intensified TB case finding in
its HIV counseling and testing centres [8]. As TB is the
most common opportunistic infection among the HIV-
infected, HIV care providers screen clients for TB signs
and symptoms and refer TB suspects to the nearest micros-
copy centre or diagnostic facility for further TB examina-
tions/tests. Despite having a relatively well functioning
national program in place, there are few published re-
ports on HIV-TB co-infections from India.Figure 1 Karnataka province, India.This paper reports on demographic and clinical char-
acteristics, and short-term treatment outcomes of HIV-
TB co-infected patients registered in the HIV program in
Karnataka, one of the highest HIV prevalence provinces
of India. Further, TB treatment outcomes in these co-
infected patients are compared with those among non-
HIV-infected TB patients registered under the National
TB Control Program within the same province.
Methods
Study design and study setting
This was a retrospective cross-sectional study using routine
program data from Karnataka province in South India.
Karnataka (Figure 1), has a population of 61.1 million
spread across 30 districts. Karnataka is one of four large
south Indian states; it experiences a relatively advanced
HIV epidemic, with the adult HIV prevalence in several
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mated 0.25 million infections. In 2007, the prevalence
among antenatal women was estimated at 0.9% [9]. The
National AIDS Control Organisation of the government
of India through its provincial wing, the Karnataka State
AIDS Prevention Society, provides anti-retroviral treatment
(ART) and follow up throughout the province through
40 district and sub-district ART centers, besides 123
link-ART centres (these are centers further in the hin-
terland which serve as points where patients living in
these areas can collect their medication to reduce travel
time and opportunity costs for patients). In addition
the state also runs 4 centers through collaborations
with reputed private health institutions in the province.
Provinces in the country follow a strategy of provider-
initiated HIV testing and counseling for all patients
registered for TB treatment as recommended by WHO
and UNAIDS. While TB treatment is initiated under the
TB program at a treatment center close to the patients
residence, the TB treatment and patient response is also
monitored by the ART center physician in case of co-
infected patients. Records of all co-infected patients being
followed up at these centers from 1 April 2010 to 31
March 2011 were analysed.
ART for HIV-infected TB patients
During the study period, the national guidelines for ART
for HIV TB co-infection followed the 2006 World Health
Organization Guidelines for ART. As per these guide-
lines, all HIV-infected persons with pulmonary TB, extra-
pulmonary or disseminated TB with a CD4-lymphocyte
count ≤350/mm3 were considered eligible for ART. The
most common ART regimen initiated was zidovudine
or stavudine plus lamivudine plus efavirenz.
TB patients in the national TB control program
In the province, tuberculosis control program services
are available through a decentralized network of primary
health care facilities which provide general health services
including diagnosis and treatment for TB. All TB patients
are treated with standardized fully intermittent thrice
weekly short-course regimens (6–9 months) adminis-
tered under direct observation and are registered at one
of the 125 sub-district level TB program management
units according to Indian program guidelines [10]. Data
for treatment outcomes for non-HIV-infected TB patients
in the same province under the RNTCP program was
obtained for patients registered between Apr 1 2010 and
Dec 31 2010.
Data collection
For HIV and TB co-infected patients, reports from each
center were obtained as excel spreadsheets which were
verified and collated. Every ART center has in its registersthe HIV infected patients registered at the respective
center who are on TB treatment. This information is
filled in by staff at the respective ART centers. These
staff provide reports on co infected patients to the
provincial level ART program office, from where the
spreadsheets of data on co-infected patients were obtained.
Data on age, sex, last (most recent) CD4 count, category
of TB treatment, ART status and TB treatment outcomes
were extracted from the records. Program outcomes were
defined as per the WHO Stop TB program. The following
TB treatment outcomes were considered: cured, treatment
completed, died, failure or defaulted.
Similarly TB program data from the DOTS program
across the province flows in from the peripheral DOTS
centers to the provincial program office. The reports
(unlike the coinfected patient reports) are summary
statistics of patients categories by outcome, and so not
contain individual characteristics of each patient.
Definitions of treatment outcomes: The national TB
control program defines: (1) “Cured” as a patient who
was initially sputum smear positive, has completed treat-
ment and had negative sputum smears on two occasions,
one of which is at the end of the treatment. If at the
end of treatment, sputum smear is not done, the patient
is classified as “treatment completed”. In case of smear
negative or extrapulmonary TB, a patient who has re-
ceived full course of treatment and has not become smear
positive at the end of the treatment is also refered to as
treatment completed. The total of “cured” and “treatment
completed” is taken as “success”. (2) “Failure” refers to
any TB patient who is smear positive at five months or
more after starting the treatment and (3) “Defaulted” is
any patient who has interrupted treatment consecutively
for more than 2 months [11].
Data analysis: Analysis was carried out in Predictive
Analytics Software, version 20 (PASW v 20). Descriptive
analysis was performed and results were expressed as
means, medians and simple proportions. Tests of signifi-
cance for differences between proportions were carried
out. Results were expressed as odds ratio and 95% CI.
Ethical approval
Ethical approval for this study was obtained from the
Institutional ethical review board of St. John’s National
Academy of Health Sciences, Bangalore, India.
Results
A total of 6,480 adult HIV-TB co-infected patients were
registered at the ART centers in the province during the
one-year study period, 35.6% of whom were women.
The mean age of the patients was 37.7 years and median
recent CD4 count was 143 cells/mm3, similar in both
men and women. First-line ART was had already been
initiated in 78% of patients diagnosed with TB. Baseline
Table 2 Comparison of treatment outcomes in patients




(n = 5079) N (%)





3,776 (74.3) 34,924 (79.9) 0.90 (0.88-0.92)
Death 797 (15.7) 3,670 (7.1) 2.22 (2.03-2.38)
Default 226 (4.4) 4,557 (8.8) 0.50 (0.44-0.58)
Failure 23 (0.5) 1,249 (2.4) 0.18 (0.12-0.28)
*Represents data from 1 Apr 2010 to 31 Mar 2011.
#Represents data from 1 Apr 2010 to 31 Dec 2011.
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were similar (mean age 38.1 and 37.5 years respectively;
63.8% and 84.2% males respectively). Nearly three-quarters
(73.2%; 4,741/6,480) of all co-infected patients had pul-
monary TB. Of these, 46% were sputum positive for acid
fast bacilli. The remaining 26.8% had extra-pulmonary
TB. Extra-pulmonary TB was seen in a higher propor-
tion of patients who had initiated ART (28.5%) than
those who had not as yet done so (14.2%) (OR = 2.4,
95% CI 2.03-2.84). The proportions of pulmonary and
extra-pulmonary TB were similar among men and women,
as were the proportions of smear positive TB. A major-
ity of the patients (87%) were new TB infections while
9.6% were those who had either defaulted treatment,
received incomplete treatment, or those who had relapsed.
Outcomes of TB treatment in HIV and TB co-infected patients
Of the 6,008 co-infected patients for whom data on TB
treatment outcomes were available, 929 were still on
treatment. Of the remaining 5079 patients, three quarters
(3,776 or 74.5%) had completed treatment successfully
(i.e. cured or treatment completed). A total of 296 pa-
tients (5.8%) had defaulted, while 22 had failed treatment.
There were 797 deaths (15.7%), with similar mortality pro-
portions in the pulmonary and extra pulmonary TB infec-
tion groups. Forty patients had not been initiated on TB
treatment because they refused treatment or wished to be
treated for their TB in the private sector. TB treatment
outcomes were significantly better for those patients who
had already initiated ART prior to their diagnosis of TB:
This compared to those who had not yet initiated ART,
had a higher proportion of treatment completions/cures,
lower rates of death, default or failure as shown in Table 1.
Outcomes in TB patients in the RNTCP program
compared with those for HIV TB co-infected patients
Treatment successes were similar among co-infected TB
patients compared to those with only TB within the
National TB program (OR= 0.9, 95% CI = 0.88-0.92). Death
rates were expectedly higher in the co-infection group
(OR = 2.22, 95% CI = 2.03-2.38). However rates of default
and treatment failure were higher among TB patients in
the TB program as shown in Table 2.Table 1 A comparison of TB treatment outcomes in HIV-TB




Not on ART (n = 1024)
N (%)





552 (54) 3191 (79.5) 1.47 (1.39-1.56)
Death 256 (25) 541 (13.5) 0.53 (0.47-0.61)
Default 105 (10.3) 118 (3) 0.28 (0.22-0.36)
Failure 10 (1) 13 (0.3) 0.33 (0.14-0.75)Discussion
This study constitutes the first report of TB treatment
outcomes in a large HIV-TB co-infection cohort in India.
Globally and in India, TB is one of the most common
opportunistic infections affecting people with HIV. This
assumes importance in a country like India which has
2.7 million HIV infections and 23% of the world’s
incident TB cases. HIV infection is often cited as an
important reason for failure to control TB, and for causing
a resurgence in TB worldwide. While this is true, our re-
sults suggest that implementation of program guidelines
in a coordinated manner can result in good treatment
outcomes among those co-infected with TB and HIV.
In this study, pulmonary involvement occurred in about
73% of all HIV infected patients with TB. This is in line
with previous reports from India [12]. Smaller studies
from Thailand have reported a lower proportion of pul-
monary TB (60%) [13] while a report from Kenya [14]
stated 87% co-infected patients had pulmonary TB. While
overall treatment success rates in our co-infected cohort
were close to 75%, they were significantly better in the
group that had been already initiated on ART compared
to those who were not on ART. Similarly, mortality rates
were twice as high in the group that had not started ART
at the time of TB treatment. Recent studies from differ-
ent countries have repeatedly shown that early initiation
of ART among co-infected individuals even during the
intensive phase of anti-tuberculous therapy can decrease
mortality among those with HIV/TB co-infection [15-18].
While from a biological point of view, patients on ART
have lower viral replication and hence better host re-
sponses, from a program point of view, these patients
are regularly clinically followed at the ART centers where
adherence is repeatedly emphasized, possibly contributing
to better outcomes in this group. This finding in our
Indian cohort lends local contextual support to the re-
cently introduced (Nov 2011) Indian program guideline
of initiating ART in all HIV-TB co-infected individuals,
as soon as possible in the intensive phase of anti-
tuberculous treatment, regardless of CD4 counts [19].
A recent study from the same province in India has
shown that only 21% of a cohort of co-infected patients
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report suggests that despite operational weaknesses
in the program, ART could be extended to all HIV-
infected TB patients irrespective of CD4 count with
relatively little additional burden on the national HIV con-
trol program [20].
Treatment success proportions in the co-infected cohort
were similar to those achieved within the routine TB con-
trol program in the province. There was an expectedly
significantly higher death rate among the co-infected
patients (16% versus 7%) in the province. Globally, TB-
associated mortality in co-infected patients is three times
higher than mortality among TB only patients. There
are a number of possible explanations that have been
proposed for the increased mortality among co-infected
patients. The location and extent of TB is influenced by
the degree of immunosuppression, often increasing the
difficulty of diagnosis and hence delaying treatment
initiation, resulting in higher mortality [21]. Immuno-
logical studies have also shown the host responses to
M. tuberculosis enhance HIV replication [22,23], thus
accelerating the natural progression of HIV and further
depressing cellular immunity. Decreased gut absorption
of anti-tuberculous drugs has been suggested by some
reports [24], leading to impaired treatment outcomes
including death. Non-initiation or delayed initiation of
ART in this cohort has also contributed to higher mor-
tality [25]. Our analysis also indicated that rates of de-
fault and failure were significantly higher among TB
only patients than in the TB HIV co-infected cohort.
This is possibly because of a significant proportion of
re-treatment patients entering the TB program (20% of
all registered patients) compared to the co-infected
cohort. In addition it is likely that the emphasis on
multidisciplinary care and adherence support to patients
within the ART program may play a role in contributing
towards the lower rates of default and failure among
the HIV/TB co-infected group, particularly among those
on ART.
This study is limited by the non-inclusion of the patients
taking ART privately. Only co-infected cases within the
ART program in the province are considered in this study,
hence the number of and outcomes for such cases not
registered in the ART program cannot be ascertained.
However this excluded group is likely to be small. The
same is also the case for patients receiving TB treatment
outside the program. The exact time duration between
initiation of ART and ATT cannot be identified reliably
from this dataset. Another limitation of the data set is
the absence of information on sites of extra pulmonary
infection. Bias is a problem as co-infected patients are
included in the main TB program registers (co-infected
patients are not removed from the registers and reported
separately), though in the summary statistical reports fromthe TB program used in this study, they are not identifi-
able as such. The strength of this study lies in the large
size of the co-infected cohort, and the results are likely to
represent the majority of those accessing HIV or TB care
in the country.
Conclusion
In summary, we have shown that TB treatment success
rates in Karnataka among the HIV/TB co-infected popu-
lation were similar to those with TB only accessing care
within the national TB control program. Moreover, co-
infected patients demonstrated lower rates of treatment
default and failure compared to those with TB only,
suggesting that the national ART guidelines with emphasis
on adherence and counseling support may have a role in
these positive outcomes. The benefit of ART on TB out-
comes in also clearly demonstrated in these results and
supports the WHO 2010 recommendation on the early
initiation of ART in co-infected cases. Ongoing efforts to
integrate TB-HIV collaborative activities will strengthen
the program further and will accelerate the march towards
TB and HIV control both nationally and globally.
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